Roxadustat Approval Might Hinge On Additional Safety Analyses After FibroGen Admits Manipulating Data

 
• By Cathy Kelly
Superior Safety Data Discredited Ahead Of FDA Panel Meeting • Source: Shutterstock

More from Clinical Trials

More from R&D